<DOC>
	<DOCNO>NCT02059681</DOCNO>
	<brief_summary>The purpose study evaluate whether endocavitary intramyocardial injection autologous bone-marrow-derived CD133+ cell safe basis number adverse event , follow-up assessment extend 1 year enrolment .</brief_summary>
	<brief_title>Phase I Trial Endocavitary Injection Bone Marrow Derived CD133+ Cells Ischemic Refractory Cardiomyopathy ( RECARDIO Trial )</brief_title>
	<detailed_description>This Phase I study investigate safety preliminary efficacy endocavitary injection bone-marrow-derived CD133+ cell 15 patient ischemic heart failure ( IHF ) eligible conventional revascularization . Patients eligible undergo bone-marrow aspiration . On day follow bone-marrow aspiration patient undergo fluoroscopy-based endocavitary intramyocardial injection target area previously identify gated-SPECT/CMR . CD133+ cell suspend physiological saline supplement 5 % human albumin solution inject myocardium via endocardial route . After discharge , efficacy follow-up last 6-months safety follow-up ( FU ) extend 1 year .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>1 . Ischemic heart failure amenable type revascularization procedure ( percutaneous surgical ) determine one interventional cardiologist one cardiovascular surgeon , 2 . Canadian Cardiovascular Society Angina functional class III IV angina and/or symptom heart failure ( NYHA score IIb IV ) stateoftheart maximal medical therapy , 3 . Left Ventricular Ejection Fraction 20 % 45 % , 4 . Peak V02 ≤ 21 mL/Kg/min , 5 . Presence reversible perfusion defect ≥ 10 % leave ventricular myocardium ( least 2 segment 20 ) determine gatedSPECT , 6.18 year ≤ Age ≤ 75 year , 7.Hemodynamic stability , 8.Ability accomplish cardiopulmonary exercise testing , 9.Are pregnant plan become pregnant study . Females childbearing potential must provide negative pregnancy test within 17 day intervention must use oral injectable contraception ( nonchildbearing potential define postmenopausal least 1 year surgical sterilization hysterectomy least 3 month study start ) , 10.A sign consent form approve institutional review board . 1 . A highrisk acute coronary syndrome ( ACS ) myocardial infarction past 3 month , 2 . Presence document unstable angina , 3 . Left ventricular thrombus , document echocardiography , 4 . Evidence lifethreatening arrhythmia , 5 . Presence severe mitral valve disease require valve replacement reconstruction , 6 . Presence mechanical aortic valve , 7 . Presence stenosis aortic valve , grade ≥+2 equivalent orifice area 1,5 cm2 less , 8 . Presence moderate severe insufficiency aortic valve , 9 . A left ventricular wall thickness &lt; 8 mm target site cell injection , assess 2D echocardiography and/or cardiac MRI , 10 . Have know , serious radiographic contrast allergy , 11 . Contraindications bonemarrow aspiration , 12 . Be organ transplant recipient , 13 . Have liver dysfunction , evidence enzyme ( AST , ALT ) &gt; 3x upper limit normal , 14 . Severe renal failure ( creatinine plasma level &gt; 2.5 mg/dl ) , 15 . A bleeding diathesis ( define INR great 1,5 reversible cause , i.e . warfarin ) , 16 . Have hematologic abnormality without explanation , 17 . Apparent infection ( creactive protein ( CPR ) &gt; 30 mg/L , fever &gt; 37 °C ) , 18 . An infectiousdisease test result positive human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C , treponema pallidum ( VDRL ) , HTLV 1 2 , 19 . Previous current document history leukemia , myeloproliferative myeloplastic disorder , 20 . Have cardiac condition limit lifespan &lt; 1 , 21 . A history malignancy past 5 year , 22 . Have history drug alcoholic abuse within past 24 month , 23 . Be chronic therapy immunosuppressant , 24 . Pregnant lactating status , 25 . Any condition , judgment investigator , would place patient undue risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>